{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:42:24Z","timestamp":1788950544578,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/mcg.0b013e318264181d","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T14:21:08Z","timestamp":1349965268000},"page":"182-187","source":"Crossref","is-referenced-by-count":81,"title":["Hepatic Steatosis in Human Immunodeficiency Virus"],"prefix":"10.1097","volume":"47","author":[{"given":"Richard K.","family":"Sterling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Brunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210305","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.285.10.1308","article-title":"Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997.","volume":"285","author":"Lee","year":"2001","journal-title":"JAMA"},{"key":"R2-19-20210305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"R3-19-20210305","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1086\/381499","article-title":"HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms.","volume":"38","author":"Pol","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"R4-19-20210305","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1086\/381448","article-title":"Pitfalls of assessing hepatotoxicity in trials and observational cohorts.","volume":"38","author":"Sabin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R5-19-20210305","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","article-title":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.","volume":"18","author":"Sulkowski","year":"2004","journal-title":"AIDS"},{"key":"R6-19-20210305","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1468-1293.2004.00232.x","article-title":"Lopinavirritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.","volume":"5","author":"Meraviglia","year":"2004","journal-title":"HIV Med"},{"key":"R7-19-20210305","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jama.292.2.243","article-title":"HIV Infection, hepatitis C infection, and HAART: hard clinical choices.","volume":"292","author":"Kottilil","year":"2004","journal-title":"JAMA"},{"key":"R8-19-20210305","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999-2002.","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"R9-19-20210305","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/432762","article-title":"Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiviral therapy.","volume":"192","author":"Rockstroh","year":"2005","journal-title":"J Infect Dis"},{"key":"R10-19-20210305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00126334-200303010-00004","article-title":"Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.","volume":"32","author":"Puoti","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-19-20210305","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1001\/jama.283.19.2526","article-title":"Elevated liver enzymes following initiation of antiretroviral therapy.","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"R12-19-20210305","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/422142","article-title":"Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.","volume":"39","author":"French","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R13-19-20210305","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/QAI.0b013e318198a88a","article-title":"Nonalcoholic fatty liver disease among HIV-infected persons.","volume":"50","author":"Crum-Cianflone","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-19-20210305","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/589294","article-title":"Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.","volume":"47","author":"Guaraldi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R15-19-20210305","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.22665","article-title":"Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy.","volume":"49","author":"Ingiliz","year":"2009","journal-title":"Hepatology"},{"key":"R16-19-20210305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.15288\/jsa.1995.56.423","article-title":"The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings.","volume":"56","author":"Bohn","year":"1995","journal-title":"J Stud Alcohol"},{"key":"R17-19-20210305","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1152\/japplphysiol.01234.2003","article-title":"Validity and reliability of dual-energy X-ray absorptiometry for the assessment of abdominal adiposity.","volume":"97","author":"Glickman","year":"2004","journal-title":"J Appl Physiol"},{"key":"R18-19-20210305","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2337\/diacare.22.8.1310","article-title":"Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome.","volume":"22","author":"Paradisi","year":"1999","journal-title":"Diabetes Care"},{"key":"R20-19-20210305","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R21-19-20210305","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease.","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"R22-19-20210305","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"The NAS and the histopathologic diagnosis of NASH: distinct clinicopathologic meanings.","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"R23-19-20210305","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1872-034X.2011.00824.x","article-title":"NASH: a global health problem.","volume":"41","author":"Sanyal","year":"2011","journal-title":"Hepatol Res"},{"key":"R24-19-20210305","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hep.23784","article-title":"Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"R25-19-20210305","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.aids.0000163935.99401.25","article-title":"Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.","volume":"19","author":"Sulkowski","year":"2005","journal-title":"AIDS"},{"key":"R26-19-20210305","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.20805","article-title":"Hepatic steatosis in HIVhepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection.","volume":"42","author":"Monto","year":"2005","journal-title":"Hepatology"},{"key":"R27-19-20210305","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1086\/497608","article-title":"Histologic findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.","volume":"192","author":"Marks","year":"2005","journal-title":"J Infect Dis"},{"key":"R28-19-20210305","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.aids.0000210606.63138.f5","article-title":"Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.","volume":"20","author":"Bani-Sadr","year":"2006","journal-title":"AIDS"},{"key":"R29-19-20210305","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.22134","article-title":"Steatohepatitis: risk factors and impact on disease severity in HIV-HCV coinfection.","volume":"47","author":"Sterling","year":"2008","journal-title":"Hepatology"},{"key":"R30-19-20210305","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/QAI.0b013e318042e1db","article-title":"Groupe dEpidemiologie Clinique du SIDA en Aquitaine. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatites virales CO3 Aquitaine Cohort.","volume":"45","author":"Neau","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-19-20210305","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1086\/505495","article-title":"Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.","volume":"43","author":"McGovern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R32-19-20210305","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2006.02.009","article-title":"Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection.","volume":"44","author":"Gaslightwala","year":"2006","journal-title":"J Hepatol"},{"key":"R33-19-20210305","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jhep.2008.01.015","article-title":"Hepatic steatosis in HIVHCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.","volume":"48","author":"Rodriguez-Torres","year":"2008","journal-title":"J Hepatol"},{"key":"R34-19-20210305","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.23619","article-title":"Hepatic steatosis in patients coinfected with human immunodeficiency virushepatitis C virus: a meta-analysis of the risk factors.","volume":"52","author":"Machado","year":"2010","journal-title":"Hepatology"},{"key":"R35-19-20210305","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/COH.0b013e3283473405","article-title":"Influence of antiretroviral therapy on liver disease.","volume":"6","author":"Kovari","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"R36-19-20210305","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.","volume":"103","author":"Dunn","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R37-19-20210305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2006.08.021","article-title":"Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.","volume":"191","author":"Targher","year":"2007","journal-title":"Atherosclerosis"},{"key":"R38-19-20210305","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/COH.0b013e328347876c","article-title":"Cardiovascular disease in HIV infection.","volume":"6","author":"Palella","year":"2011","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004836-201302000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:28:04Z","timestamp":1618036084000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201302000-00019"}},"subtitle":["A Prospective Study in Patients Without Viral Hepatitis, Diabetes, or Alcohol Abuse"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e318264181d","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}